JCR Pharmaceuticals News

JCR Pharmaceuticals: Financial summary of the consolidated performance for the three months until June 30, 2024 (fiscal year 2024) (Japanese standard) (preliminary report).

Jul 30 03:00 ET

JCR Pharmaceuticals: 2024 Annual Q1 Earnings Conference Call

Jul 30 03:00 ET

JCR Pharmaceuticals: Overview of Q1 2025 earnings report.

Jul 30 03:00 ET

JCR Pharmaceuticals: Announcements of individual stocks: Development of "Temcell HS injection" for neonatal hypoxic ischemic encephalopathy has been discontinued for expansion of indication (development code: JR-031HIE).

Jul 30 03:00 ET

JCR Pharmaceuticals: JCR Pharmaceuticals has announced the discontinuation of TEMCELL HS Inj manufacture, expanding the indications for developing neonatal hypoxic-ischemic encephalopathy.

Jul 30 03:00 ET

JCR Pharmaceuticals: Announcements of individual stocks regarding disposal of treasury stock as share-based compensation with transfer restrictions.

Jul 23 03:00 ET

JCR Pharmaceuticals: JCR Pharmaceuticals emphasizes innovative gene therapy research at the 7th International Forum on Lysosomal Diseases.

Jul 18 03:00 ET

JCR Pharmaceuticals: Announcements of individual stocks: Notice of research presentation at the 7th International Lysosomal Disease Forum.

Jul 18 03:00 ET

JCR Pharmaceuticals: JCR held an API factory tour for local residents.

Jul 5 02:30 ET

JCR Pharmaceuticals: We held a factory tour for local residents.

Jul 5 02:30 ET

JCR Pharmaceuticals: Announcements of individual stock: [Delayed] Notice of personnel and organizational changes.

Jul 3 03:00 ET

JCR Pharmaceuticals: MEDIPAL and JCR have announced the completion of the clinical trial notification process for the phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB in Japan.

Jul 1 03:00 ET

JCR Pharmaceuticals: Acceptance of the investigational plan for Phase I/II trials of JR-446 for Mucopolysaccharidosis IIIB and completion of regulatory authority investigation regarding the clinical trial plan.

Jul 1 03:00 ET

JCR Pharmaceuticals: Announcements of individual stocks regarding personnel changes and organizational restructuring.

Jun 26 03:00 ET

JCR Pharmaceuticals: Matters related to the controlling shareholder (affiliated company).

Jun 26 03:00 ET

JCR Pharmaceuticals: Regarding matters related to major shareholders (other affiliated companies).

Jun 26 03:00 ET

JCR Pharmaceuticals: Correction: Consolidated financial statements (Japanese GAAP) for the fiscal year ending March 31, 2024 (fiscal year 2023)

Jun 26 03:00 ET

JCR Pharmaceuticals: JCR Pharmaceuticals will regain full commodity rights for JR-141.

Jun 25 05:30 ET

JCR Pharmaceuticals: Reacquisition of global sales rights for JR-141.

Jun 25 05:30 ET

JCR Pharmaceuticals: Independent Officer Notification Form

Jun 3 04:00 ET